The neural and neuroimmune mechanisms behind myocardial infarction-triggered cardiac events, immune responses and activation of the nervous system remain largely unexplored. The heart and the brain ...
Hidradenitis suppurativa (HS) is a chronic autoinflammatory condition affecting the skin, the genetic mechanisms of which are ...
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it ...
Affinia Therapeutics Inc. has obtained IND clearance from the FDA for AFTX-201, an investigational genetic medicine for the ...
The U.K.’s main research funding agency is looking to put more public money into proof of concept and pre-seed funding of putative university spinouts, to make them more investible and improve ...
Amgen Inc.’s head of R&D James Bradner said his firm was “surprised” by the request from the U.S. FDA Jan. 16 to take Tavneos ...
The BioWorld Cancer Index closed 2025 up 72.35%, outpacing gains in the Nasdaq Biotechnology Index (up 32.4%) and the Dow ...
D-glucosaminidase (O-GlcNAcase; OGA) inhibitors described as potentially useful for the treatment of cancer, metabolic diseases, Alzheimer’s disease and progressive supranuclear palsy.
Despite reporting strong fourth-quarter (Q4) organic sales growth of $5.29 billion, up 12.7% year-on-year, Boston Scientific ...
Researchers at Tangram Therapeutics Inc. have presented preclinical safety and efficacy data for TGM-148 in a model of von Willebrand disease.
The melanin-concentrating hormone (MCH) is one of the most potent central stimulators of feeding and regulates energy balance. Therefore, agonists of the melanin-concentrating hormone MCH1 receptor ...
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in lipid nanoparticles.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results